XTalks

AUGUST 2, 2023

We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

NOVEMBER 5, 2020

and Aavis Pharmaceuticals Inc. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. D/B/A Aavis Pharmaceuticals. About Jubilant Cadista Pharmaceuticals Inc. YARDLEY, Pa.

Marketing 40

Marketing Generic Pharmaceutical Contract Manufacturing Manufacturing 40

The Pharma Data

DECEMBER 23, 2020

. Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX’s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. The Company is marketing these products globally, in over 150 countries.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

DECEMBER 23, 2020

COVAXX is committed to providing an equitable distribution of UB-612 vaccine by prioritizing markets where the unmet need is greatest,” said Mei Mei Hu, co-founder and CEO of COVAXX. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52